NFL Biosciences (XPAR:ALNFL) EBIT: €-3.84 Mil (TTM As of Dec. 2025)


XPAR:ALNFL NFL Biosciences SA XPAR:ALNFL
29 GF Score
Price €0.86
! 1 Warning Sign
View Full Analysis

What is NFL Biosciences EBIT?

NFL Biosciences XPAR:ALNFL -1.49% 29 EBIT is €-3.84 Mil as of Dec. 2025. GuruFocus rates XPAR:ALNFL with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

NFL Biosciences's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was €-1.73 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.84 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NFL Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 was -141.03%. NFL Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3,264.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NFL Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -41.59%.

NFL Biosciences  (XPAR:ALNFL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NFL Biosciences's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-3.502 * ( 1 - 12.69% )/( (1.911 + 2.425)/ 2 )
=-3.0575962/2.168
=-141.03 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.423 - 0.973 - ( 3.128 - max(0, 2.603 - 4.142+3.128))
=1.911

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.663 - 0.755 - ( 2.202 - max(0, 2.922 - 3.405+2.202))
=2.425

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

NFL Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-3.46/( ( (0.111 + max(-2.547, 0)) + (0.101 + max(-2.537, 0)) )/ 2 )
=-3.46/( ( 0.111 + 0.101 )/ 2 )
=-3.46/0.106
=-3,264.15 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.026000000000001) - (0.973 + 0 + 1.6)
=-2.547

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.237) - (0.755 + 0 + 2.019)
=-2.537

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NFL Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-3.843/9.241
=-41.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences EBIT Related Terms

NFL Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for NFL Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences EBIT Chart

NFL Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -1.12 -2.86 -4.11 -2.72 -3.84

NFL Biosciences Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.80 -0.85 -1.86 -2.11 -1.73

XPAR:ALNFL vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, NFL Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NFL Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's EV-to-EBIT falls into.


XPAR:ALNFL
29GF Score
NFL Biosciences SA XPAR:ALNFL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NFL Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-3.84 Mil mean?
NFL Biosciences (XPAR:ALNFL) has a EBIT of €-3.84 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NFL Biosciences.
Is NFL Biosciences' EBIT too high?
NFL Biosciences' current EBIT is €-3.84 Mil. Overall, NFL Biosciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does NFL Biosciences' EBIT compare to VRTX and REGN?
NFL Biosciences' EBIT of €-3.84 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NFL Biosciences. NFL Biosciences's current EBIT is €-3.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NFL Biosciences stock overvalued right now?
NFL Biosciences (XPAR:ALNFL) has a current EBIT of €-3.84 Mil. The current EBIT is €-3.84 Mil. NFL Biosciences' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For NFL Biosciences (XPAR:ALNFL), the current EBIT is €-3.84 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NFL Biosciences Business Description

Other Exchanges 82F:Germany
Address 199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
29GF Score

Get the complete analysis for XPAR:ALNFL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price